UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 22, 2021

AXOGEN, INC.

(Exact Name of Registrant as Specified in Charter)

Minnesota	**001-36046**	**41-1301878**
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

13631 Progress Boulevard, Suite 400 Alachua, Florida	**32615**
(Address of principal executive offices)	(Zip Code)

(386) 462-6800
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock, $0.01 par value	AXGN	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On February 22, 2021, Axogen, Inc. (the "Company") issued a press release announcing its fourth quarter and full year 2020 revenue. A copy of the press release is furnished as Exhibit 99.1.

The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended (the "Securities Act"), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

Item 7.01 Regulation FD Disclosure.

On February 22, 2021, the Company also posted an updated corporate presentation to its website at https://ir.axogeninc.com/news-events. The Company may use the investor presentation from time to time in conversation with analysts, investors, and others. A copy of the investor update is furnished as Exhibit 99.2.

The information in this Item 7.01, including Exhibit 99.2, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any filing under the Securities Act or Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Axogen, Inc. Press Release, dated February 22, 2021.
99.2	Axogen, Inc. Corporate Presentation, dated February 22, 2021.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AXOGEN, INC.

Date: February 22, 2021

By: /s/ Brad Ottinger

Brad Ottinger

General Counsel and Chief Compliance Officer

Axogen, Inc. Reports 2020 Fourth Quarter and Full-Year Financial Results

ALACHUA, FL – February 22, 2021 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020.

Fourth Quarter 2020 Financial Results and Business Highlights

- Net revenue was $32.5 million during the quarter, a 15% increase compared to fourth quarter 2019 revenue of $28.2 million.
- Gross margin was 83.2% for the quarter, compared to 82.7% in the fourth quarter of 2019.
- Net loss for the quarter was $6.0 million, or $0.15 per share, compared to a net loss of $7.0 million, or $0.18 per share, in the fourth quarter of 2019.
- Adjusted net loss was $3.3 million for the quarter, or $0.08 per share, compared with adjusted net loss of $4.0 million, or $0.10 per share, in the fourth quarter of 2019.
- Adjusted EBITDA loss was $2.1 million for the quarter, compared to an adjusted EBITDA loss of $4.2 million in the fourth quarter of 2019.
- The balance of cash, cash equivalents, and investments on December 31, 2020 was $110.8 million, compared to a balance of $106.7 million on September 30, 2020. The net increase includes $3.5 million of equity proceeds received from Oberland Capital related to the option exercise associated with their debt facility, positive operating cash flow in the quarter of $3.4 million, partially offset by capital expenditures of $2.8 million related to our new facilities in Tampa and Dayton.
- Active accounts in the fourth quarter were 893, a 12% increase compared to 797 in the fourth quarter a year ago, and revenue from the top 10% of our active accounts continued to represent approximately 35% of total revenue in the quarter.

“Our fourth quarter and 2020 results are a testament to the resilience of our Axogen team and the ability to successfully execute our focused strategy while also managing the challenges associated with the COVID-19 pandemic,” said Karen Zaderej, chairman, CEO, and president of Axogen, Inc. “We adapted quickly and met each challenge with innovative thinking and a patient-first approach. As a result of the efficiencies and skills gained, we are now even better positioned to meet the growing surgeon demand for our evidence-based nerve repair solutions.”

Full-Year 2020 Financial Results and Business Highlights

- Full-year 2020 revenue was $112.3 million, a 5% increase compared to 2019 revenue of $106.7 million.

- Gross margin was 80.8% for the full year, compared to 83.7% in 2019.
- Net loss for the full year was $23.8 million, or $0.60 per share, compared to $29.1 million, or $0.74 per share, in 2019.
- Adjusted net loss was $15.3 million for the full year, or $0.38 per share, compared to $16.4 million, or $0.42 per share, in 2019
- Adjusted EBITDA loss was $13.1 million for the full year, compared to an adjusted EBITDA loss of $17.7 million in 2019.
- Ended the year with 111 direct sales representatives, compared to 109 at the end of 2019.
- Ended the year with 147 peer-reviewed clinical publications featuring Axogen's nerve repair product portfolio.
- Surpassed 50,000 Avance® Nerve Grafts implanted since launch.

Conference Call
The Company will host a conference call and webcast for the investment community today at 4:30 p.m. ET. Investors interested in participating by phone are invited to call toll free at 1-877-407-0993 or use the direct dial-in number 1-201-689-8795. Those interested in listening to the conference call live via the Internet can do so by visiting the Investors page of the Company's website at www.axogeninc.com and clicking on the webcast link on the Investors home page.

Following the conference call, a replay will be available on the Company's website at www.axogeninc.com under Investors.

About Axogen
Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive® Soft Tissue Membrane, a processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier. The Axogen portfolio

of products is available in the United States, Canada, Germany, United Kingdom, Spain, South Korea, and several other countries.

Cautionary Statements Concerning Forward-Looking Statements

This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements related to the expected impact of COVID-19 on our business, statements regarding our growth, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our assessment of our internal controls over financial reporting, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this press release should be evaluated together with the many uncertainties that affect our business and our market, particularly those discussed under Part I, Item 1A., “Risk Factors,” of our Annual Report on Form 10-K, as amended on Form 10-K/A, for the fiscal year ended December 31, 2019, as well as other risks and cautionary statements set forth in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances, or otherwise.

About Non-GAAP Financial Measures

To supplement our consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, and Adjusted EBITDA which further excludes non-cash stock compensation expense and litigation and related expenses. We also use the non-GAAP financial measures of Adjusted Net Income or Loss and Adjusted Net Income or Loss Per Common Share - basic and diluted which excludes non-cash stock compensation expense and litigation and related expenses from Net Loss and Net Loss Per Common Share - basic and diluted, respectively. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of Axogen’s GAAP financial measures to the corresponding non-GAAP measures should be carefully evaluated.

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our

performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.

Contact:
Axogen, Inc.
Peter J. Mariani, Chief Financial Officer
pmariani@axogeninc.com
InvestorRelations@axogeninc.com

AXOGEN, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)

	December 31, 2020	December 31, 2019
Assets		
Current assets:		
Cash and cash equivalents	$ 48,767	$ 35,724
Restricted Cash	6,842	6,000
Investments	55,199	60,786
Accounts receivable, net	17,618	16,944
Inventory	12,529	13,861
Prepaid expenses and other	4,296	1,706
Total current assets	145,251	135,021
Property and equipment, net	38,398	14,887
Operating lease right-of-use assets	15,614	3,133
Finance lease right-of-use assets	64	87
Intangible assets	2,054	1,515
Total assets	$ 201,381	$ 154,643
Liabilities and Shareholders' Equity		
Current liabilities:		
Accounts payable and accrued expenses	$ 21,968	$ 19,144
Current maturities of lease liabilities	863	1,736
Total current liabilities	22,831	20,880
Long-term debt, net of financing fees	32,027	—
Debt derivative liability	2,497	—
Long-term lease obligations	20,874	1,595
Other long-term liabilities	3	15
Total liabilities	78,232	22,490
Shareholders' equity:		
Common stock, $.01 par value; 100,000,000 shares authorized; 40,618,766 and 39,589,775 shares issued and outstanding	406	396
Additional paid-in capital	326,390	311,618
Accumulated deficit	(203,647)	(179,861)
Total shareholders' equity	123,149	132,153
Total liabilities and shareholders' equity	$ 201,381	$ 154,643

AXOGEN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three and Twelve Months ended December 31, 2020 and 2019
(unaudited)

	Three Months Ended		Fiscal Year Ended	
	Dec 31, 2020	Dec 31, 2019	Dec 31, 2020	Dec 31, 2019
Revenues	$ 32,495	$ 28,162	$ 112,300	$ 106,712
Cost of goods sold	5,463	4,881	21,581	17,349
Gross profit	27,032	23,281	90,719	89,363
Costs and expenses:				
Sales and marketing	19,805	18,804	69,659	71,950
Research and development	4,931	4,912	17,846	17,514
General and administrative	7,670	6,984	26,396	31,305
Total costs and expenses	32,406	30,700	113,901	120,769
Loss from operations	(5,374)	(7,419)	(23,182)	(31,406)
Other income (expense):				
Interest income	29	439	605	2,364
Interest expense	(595)	(8)	(1,054)	(40)
Change in fair value of derivative liabilities	(46)	—	(117)	—
Other expense	(24)	(50)	(38)	(53)
Total other expense	(636)	381	(604)	2,271
Net loss	$ (6,010)	$ (7,038)	$ (23,786)	$ (29,135)
Weighted average common shares outstanding – basic and diluted	40,246	39,485	39,967	39,235
Loss per common share – basic and diluted	$ (0.15)	$ (0.18)	$ (0.60)	$ (0.74)
Adjusted net loss - non GAAP	(3,265)	(3,978)	(15,281)	(16,364)
Adjusted net loss per common share - basic and diluted	$ (0.08)	$ (0.10)	$ (0.38)	$ (0.42)

AXOGEN, INC.
RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES
Three and Twelve Months ended December 31, 2020 and 2019
(unaudited)

	Three Months Ended		Fiscal Year Ended	
	Dec 31, 2020	Dec 31, 2019	Dec 31, 2020	Dec 31, 2019
Net loss	$ (6,010)	$ (7,038)	$ (23,786)	$ (29,135)
Depreciation and amortization expense	556	299	1,660	1,056
Investment income	(29)	(439)	(605)	(2,364)
Income tax	77	(52)	77	(67)
Interest expense	595	8	1,054	40
EBITDA - non GAAP	$ (4,811)	$ (7,222)	$ (21,600)	$ (30,470)
Non cash stock compensation expense	2,745	2,920	8,470	10,304
Litigation and related costs	—	140	35	2,467
Adjusted EBITDA - non GAAP	$ (2,066)	$ (4,162)	$ (13,095)	$ (17,699)
Net loss	$ (6,010)	$ (7,038)	$ (23,786)	$ (29,135)
Non cash stock compensation expense	2,745	2,920	8,470	10,304
Litigation and related costs	—	140	35	2,467
Adjusted Net Loss - non GAAP	$ (3,265)	$ (3,978)	$ (15,281)	$ (16,364)
Weighted average common shares outstanding – basic and diluted	40,246	39,485	39,967	39,235
Adjusted net loss per common share - basic and diluted	$ (0.08)	$ (0.10)	$ (0.38)	$ (0.42)

AXOGEN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
Fiscal Year Ended December 31, 2020 and 2019
(unaudited)

	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total Shareholders' Equity
For the Three Months Ended December 31, 2020:				
Balance at September 30, 2020	$ 401	$ 318,949	$ (197,637)	$ 121,713
Net Loss	-	-	(6,010)	(6,010)
Stock-based compensation	-	2,745	-	2,745
Shares surrendered by employees to pay tax withholdings	1	(6)		(5)
Issuance of common stock from exercise of option (Oberland)	2	3,680	-	3,682
Exercise of stock options and employee stock purchase plan	2	1,022	-	1,024
Balance at December 31, 2020	$ 406	$ 326,390	$ (203,647)	$ 123,149
For the Fiscal Year Ended December 31, 2020:				
Balance at December 31, 2019	$ 396	$ 311,618	$ (179,861)	$ 132,153
Net Loss	-	-	(23,786)	(23,786)
Stock-based compensation		8,470	-	8,470
Shares surrendered by employees to pay tax withholdings	-	(670)	-	(670)
Issuance of common stock from exercise of option (Oberland), net of derivative	2	3,680	-	3,682
Issuance of restricted and performance stock units	2	(2)	-	-
Exercise of stock options and employee stock purchase plan	6	3,294	-	3,300
Balance at December 31, 2020	$ 406	$ 326,390	$ (203,647)	$ 123,149
For the Three Months Ended December 31, 2019:				
Balance at September 30, 2019	$ 395	$ 307,839	$ (172,823)	$ 135,411
Net Loss	-	-	(7,038)	(7,038)
Issuance of common stock	-	-	-	-
Stock-based compensation	-	2,919	-	2,919
Exercise of stock options and employee stock purchase plan	1	860	-	861
Balance at December 31, 2019	$ 396	$ 311,618	$ (179,861)	$ 132,153
For the Fiscal Year Ended December 31, 2019:				
Balance at December 31, 2018	$ 389	$ 297,319	$ (150,726)	$ 146,982
Net Loss	-	-	(29,135)	(29,135)
Stock-based compensation	-	10,304	-	10,304
Exercise of stock options and employee stock purchase plan	7	3,995	-	4,002
Balance at December 31, 2019	$ 396	$ 311,618	$ (179,861)	$ 132,153

AXOGEN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Fiscal Year Ended December 31, 2020 and 2019
(unaudited)

	Fiscal Year	
	December 2020	**December 2019**
Cash flows from operating activities:		
Net loss	$ (23,786)	$ (29,135)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	1,507	933
Amortization of right-of-use assets	1,800	1,821
Amortization of intangible assets	153	123
Write-down of trademark	-	104
Loss on disposal of assets	3	—
Amortization of deferred financing costs	232	—
Change in fair value of derivatives	117	—
Provision for bad debt	(105)	514
Provision for inventory write down	2,242	1,887
Change in investment gains and losses	(47)	(972)
Share-based compensation	8,470	10,304
Change in assets and liabilities:		
Accounts receivable	(635)	(2,136)
Inventory	(910)	(3,767)
Prepaid expenses and other	(2,524)	(661)
Accounts payable and accrued expenses	4,958	2,920
Operating Lease Obligations	(1,086)	(1,773)
Cash paid for interest portion of Finance Leases	(3)	(4)
Contract and other liabilities	(12)	(30)
Net cash used in operating activities	(9,626)	(19,872)
Cash flows from investing activities:		
Purchase of property and equipment	(21,905)	(4,664)
Purchase of short-term investments	(77,806)	(121,074)
Sale/Maturities of short-term investments	83,440	153,571
Cash payments for intangible assets	(692)	(562)
Net cash provided by/ (used for) investing activities	(16,963)	27,271
Cash flows from financing activities:		
Proceeds from the issuance of common stock	3,500	—
Proceeds from the issuance of long-term debt	35,000	—
Proceedsfrom the paycheck protection program	7,820	—
Repayment of the paycheck protection program	(7,820)	—
Payment of debt issuance costs	(642)	—
Payments of employee tax withholding in exchange of common stock	(670)	—
Cash paid for debt portion of finance leases	(14)	29
Proceeds from exercise of stock options and warrants	3,300	4,002
Net cash provided by financing activities	40,474	4,031
Net increase in cash, cash equivalents and restricted cash	13,885	11,430
Cash, cash equivalents and restricted cash, beginning of year	41,724	30,294
Cash, cash equivalents and restricted cash, end of period	$ 55,609	$ 41,724
Supplemental disclosures of cash flow activity:		
Cash paid for interest	$ 822	$ 34
Supplemental disclosure of non-cash investing and financing activities		
Acquisition of fixed assets in accounts payable and accrued expenses	$ 1,077	$ 3,212
Acquisition of leasehold asset	$ 5,250	$ -
Right-of-use asset and operating lease liability	$ 14,259	$ 26
Embedded derivative associated with the long term debt	$ 2,563	$ -
Conversion of the Oberland Option	$ 182	$ -

Corporate presentation

As of December 31, 2020

nasdaq: axgn

axogen®

Safe harbor statement

This presentation contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements related to the expected impact of COVID-19 on our business, statements regarding our growth, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our assessment of our internal controls over financial reporting, our visibility at and sponsorship of conferences and educational events.

The forward-looking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this press release should be evaluated together with the many uncertainties that affect our business and our market, particularly those discussed under Part I, Item 1A., “Risk Factors,” of our Annual Report on Form 10-K, as amended on Form 10-K/A, for the fiscal year ended December 31, 2019, as well as other risks and cautionary statements set forth in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances, or otherwise.

The Axogen platform for nerve repair

The function of nerves

Nerves are like wires

- Transfer signals across a network
- If cut, data cannot be transferred
- If crushed, short circuits and data corruption may occur



The peripheral nervous system is a vast network from every organ to and from the brain

- Sensory
- Motor
- Autonomic

Axogen is the preeminent nerve repair company with a foundation for long-term sustainable growth

- ✓ Exclusively focused on peripheral nerve repair across an expanding set of applications addressing a large market opportunity
- ✓ Differentiated platform for nerve repair, anchored by Avance® Nerve Graft
- ✓ 10+ years of demonstrated clinical consistency and meaningful recovery outcomes
- ✓ 147 peer-reviewed clinical publications featuring the Axogen product portfolio
  (as of December 31, 2020)
- ✓ More than 50,000 Avance Nerve Grafts have been implanted since launch
- ✓ Avance RMAT designation highlights clinical evidence strength and unmet medical need for improved nerve injury treatments
- ✓ Commercial and Professional Education capability to convert experienced surgeons while training the next generation
- ✓ Significant barriers to competitive entry
- ✓ Solid balance sheet provides resources to execute business plan
- ✓ Experienced management team with strong track record of success

Delivering strong, consistent revenue growth & gross margins

U.S. $ in millions



Operational Highlights

- Revenue growth of 15% for Q4 and 5% for full year 2020, despite the continued dampening effect of COVID-19
- Executing our strategy of driving adoption in our largest market opportunity of extremity trauma
- More than 50,000 Avance Nerve Grafts have been implanted since launch
- REPOSE[SM] pilot study demonstrated clinically significant improvements for subjects with chronic neuropathic pain

83.2% Gross Margin for the quarter ended December 31, 2020
80.8% Gross Margin for the year ended December 31, 2020

How are nerves injured?

Connect	**Transection** Traumatic nerve injuries e.g., motor vehicle accidents, power tool accidents, battlefield injuries, gunshot wounds, surgical injuries, neuromas in continuity
Protect	**Compression** Carpal, cubital, tarsal tunnel revisions, blunt trauma, previous surgeries
Terminate	**Stump Neuroma** Amputations, mastectomies, previous surgeries

Current targeted nerve markets (U.S.)

>$2.7 Billion*



U.S. potential procedural estimates >900,000**

- Trauma: > 700,000[1,2,3,4]
- Carpal Tunnel Revisions & Cubital Tunnel: 130,000[5,6,7,8]
- OMF: > 55,000[9,10,11,12,13,14,15,16,17]
- Breast Neurotization Procedures: 15,000[18]

*$2.7B estimate does not include pain market

**Referenced papers were used to derive specific assumptions in the procedure potential estimates. Papers used include both U.S. and OUS databases and studies.

Estimated $2.7B value of market opportunity in existing applications

	Annual Incidence[a]	×	Weighted Average Procedure Value	=	Total Addressable Market
Trauma	700,000[b]		$2,725[c]		$1,900M
Carpal and Cubital Tunnel	130,000		$2,100		$270M
Oral and Maxillo-Facial (OMF)	56,000		$5,400		$300M
Breast Reconstruction Neurotization	24,500 flaps (15,000 patients)		$10,200		$250M
Totals	>900,000 (potential)				>$2.7B

a) Annual incidence of PNI surgery are figures rounded to the nearest thousandth except for Breast Reconstruction Neurotization (rounded to nearest hundredth).
b) See slides 9 and 10 for further details.
c) Includes factor of 1.22 nerves by procedure based upon data observed in the RANGER® registry.

Trauma total addressable market

Patient Population[a]	Source	Adjustments and Rationale
136,943,000 Annual emergency department visits in the U.S.	2015 National Hospital Ambulatory Medical Care Survey (Table 1)	
30,238,000 Annual emergency department visits due to injury in the U.S. ✖ **4.76%** Percentage of emergency department visits with nerve injury	2015 National Hospital Ambulatory Medical Care Survey (Table 18) *Noble, et al: J Trauma, Volume 45(1) July 1998.116-122*	• Adjusted from 38,959,000 to exclude 8,721,000 injuries that are unlikely to include a nerve injury (i.e., mental disorders, skin conditions, etc.) • 2.8% rate cited in *Noble, et al* study excluded 113 patients coded with nerve injuries outside of the study scope, but that are in the Axogen scope of nerve repair (brachial plexus and digital nerve injuries). Including these injuries increases the rate to 4.76%.
1,440,000 Annual emergency department visits with nerve injury in the U.S. ✖ **46.2%** Percentage of ED nerve injuries estimated to be treated surgically	*Noble, et al: J Trauma, Volume 45(1) July 1998.116-122*	• Calculated rate based on various rates in *Noble et al* study for upper and lower extremity and an estimate for other trauma nerves.
~665,000 **Annual ED visits with nerve injury estimated to be treated surgically in the U.S., excluding revisions**		

a) Patient population figures rounded to the nearest thousandth.

Trauma total addressable market (continued)

Patient Population[a]	Source	Adjustments and Rationale
~665,000 Annual emergency department visits with nerve injury that can be treated surgically in the U.S., excluding revisions ✖ 7.4% Revision cases	See calculation on previous slide *Portincasa et al: Microsurgery 27:455-462, 2007*	• *Portincasa et al* suggests that a revision procedure was necessary in 7.4% of the patients within 6 months of the initial surgery.
= 714,000 Annual emergency department visits with nerve injury that can be treated surgically in the U.S., including revisions ↓ ~700,000 **Company estimate of trauma total addressable market**		

a) Patient population figures rounded to the nearest thousandth.

Traditional TRANSECTION repair options are suboptimal

SUTURE

Direct suture repair of no-gap injuries

- Common repair method
- May result in tension to the repair leading to ischemia
- Concentrates sutures at the coaptation site



AUTOGRAFT

Traditional method despite several disadvantages

- Secondary surgery
- Loss of function and sensation at harvest site
- 27% complication rate including infection, wound healing and chronic pain [19]
- Limited availability of graft length and diameter



SYNTHETIC CONDUITS

Convenient off the shelf option; limited efficacy & use

- Provides only gross direction for regrowth
- Limited to small gaps
- 34%-57% failure rate >5mm gaps[20, 21]
- Semi-rigid and opaque material limits use and visualization
- Repair reliant on fibrin clot formation



Axogen solutions for TRANSECTION repair

avance® nerve graft



Processed human nerve allograft for bridging nerve gaps

Clinically studied off-the-shelf alternative

- A biologically active nerve therapy with more than ten years of comprehensive clinical evidence
- 82-84% meaningful recovery in sensory, mixed and motor nerve gaps in multi-center study[22]
- Eliminates need for an additional surgical site and risks of donor nerve harvest[22]
- Reduces OR time as compared to traditional autograft[57, 59]

Structural support for regenerating axons

- Cleansed and decellularized extracellular matrix (ECM)
- Offers the benefits of human peripheral nerve micro-architecture and handling

Revascularizes and remodels into patient's own tissue similar to autologous nerve[23]

16 size options in a variety of lengths (up to 70mm) and diameters (up to 5mm)

axoguard® nerve connector



Only minimally processed porcine ECM for connector-assisted coaptation

Alternative to direct suture repair

- Reduces the risk of forced fascicular mismatch[24, 25]

Alleviates tension at critical zone of regeneration

- Disperses tension across repair site[26]
- Moves suture inflammation away from coaptation face[27, 28]

ECM allows for vascularization, gradually remodeling and incorporating into the patient's own tissue[28, 29, 30, 31, 34]

Traditional COMPRESSION repair options are suboptimal

VEIN WRAPPING

Autologous vein

- Barrier to attachment to surrounding tissue
- Requires extra time and skill to perform spiral wrapping technique
- Second surgery site



HYPOTHENAR FAT PAD

Autologous vascularization flap

- Barrier to attachment to surrounding tissue
- Only wraps part of the nerve circumference
- Increases procedure time



COLLAGEN WRAPS

Off-the-shelf

- Semi-rigid material limits use
- Degrades over time and does not provide a lasting barrier to soft tissue attachment

Axogen solutions for COMPRESSION repair

axoguard® nerve protector



Minimally processed porcine extracellular matrix for wrapping and protecting injured peripheral nerve

Protects repair site from surrounding tissue

- Processing results in an implant that works with the body's natural healing process[32]
- Minimizes soft tissue attachments[33]

Allows nerve gliding

- Minimizes risk of entrapment[33]
- Creates a barrier between repair and surrounding tissue bed[33]
- ECM revascularizes and remodels into patient's own tissue[29,34]

avive® soft tissue membrane

Processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier

Smart processing to preserve the natural properties of the umbilical cord amniotic membrane

Designed with the surgeon in mind

- Easy to handle, suture, or secure during a surgical procedure
- Up to 8x thicker than placental amniotic membrane alone[35]
- Specifically designed as a resorbable soft tissue barrier to separate the tissue layers for at least 16 weeks[36]

Traditional STUMP NEUROMA options are suboptimal

TRACTION NEURECTOMY

Nerve placed in traction and cut to allow for retraction

- Simply resecting the nerve results in subsequent neuroma formation and risk of secondary surgery
- Causes traction injury
- High risk of recurrence[37]



BURYING IN MUSCLE/BONE

Traditional method of neurectomy and neuromyodesis

- Simply resecting the nerve results in subsequent neuroma formation and risk of secondary surgery
- Pain due to muscular contraction or localized pressure
- Larger surgical dissection
- Only 33-40% of patients were satisfied with treatment after burial into bone or muscle[38, 39, 40]



INJECTIONS

Pharmacologic intervention, typically alcohol or steroids[41, 42, 43, 44, 45, 46]

- Chemical injections are only successful 40% of the time[44, 45]
- Temporary solution that has a reduced benefit over time
- May cause considerable side effects

Axogen solution for STUMP NEUROMA

axoguard® nerve cap



Proprietary SIS matrix designed to separate the nerve end from the surrounding environment to protect it from mechanical stimulation and reduce painful neuroma formation.

Protects and isolates

- Reduces the development of symptomatic or painful neuroma
- Provides a barrier from neurotrophic factors and mechanical stimulation

SIS Material allows for vascularization and gradual remodeling (as shown in animal studies)[47, 48]

- Material gradually incorporates into patient's own tissue, creating a physical barrier to surrounding soft tissue

Intra-operative versatility

- Ideal for anatomic areas with limited or no musculature
- Alternative to historical techniques such as burying in muscle or bone
- Available in a variety of diameters

Axogen's comprehensive platform for addressing nerve injuries

one company for all your surgical nerve repair solutions

avance® nerve graft

Biologically active, processed human nerve allograft developed for bridging nerve discontinuities up to 70 mm

axoguard® nerve connector

Semi-translucent coaptation aid for nerve transections up to 5 mm

axoguard® nerve protector

Extracellular matrix that remodels to protect injured nerves and reinforce nerve reconstructions

avive® soft tissue membrane

Resorbable soft tissue covering to separate tissue layers for at least 16 weeks

axoguard® nerve cap

Separates nerve end from surrounding environment to protect from mechanical stimulation and reduce painful neuroma formation

Connection	Protection	Termination

axogen® revolutionizing the science of nerve repair™

Avance IP and regulatory barriers to competitive entry



Unique Avance technology creates barriers to competitive entry

Progress toward Biologics License Application (BLA) for Avance Nerve Graft

- Received Regenerative Medicine Advanced Therapy (RMAT) designation for Avance Nerve Graft in September 2018
  - Highlights strength of clinical evidence and the unmet medical need for improved therapies to treat nerve injuries

- RECON[SM] target enrollment of 220 subjects was reached in July 2020
  - Prospective randomized controlled double-blinded study compares Avance Nerve Graft to synthetic conduits in digital injuries
  - The protocol includes a 12-month follow-up visit for all subjects; and, given the impact of COVID-19, our plans allow for an additional three months for the subjects to complete their final visit. We anticipate the final visit to occur no later than October of 2021
  - Preliminary study data report expected in Q2 2022
  - Expect to file BLA in 2023

- Expected protection from potential biosimilars – 12-year data exclusivity from date of BLA approval

- Building a new 107,000 square foot, state-of-the-art biologics processing facility
  - Facility being built to cGMP standards under 21 CFR Part 210/211 regulations
  - Supports long term capacity expansion
  - Restarted construction of facility in January 2021, after temporary suspension as part of COVID-19 cost mitigation initiatives, and anticipate transition of tissue processing by late 2022

Market development strategy



Focus on building awareness among clinicians and patients

- Increased multi-channel engagement with clinicians and patients
- Continuing clinical conference participation virtually
- Ongoing patient ambassador program
- Garnering positive media attention
- Growing social media presence

Emphasis on education

- Converted national education programs to virtual platforms
- Providing customized multimodal learning programs to specific surgeon cohorts for advanced learning
- Ongoing interactive webinar series covering the principles of nerve repair
- Train three-quarters of all hand and micro-surgery fellows annually

Educate Surgeons, Develop Advocates

Strong commitment to developing clinical evidence

RANGER® Registry Study: Enrollment Ongoing

- The largest multi-center clinical study in peripheral nerve repair with >2,300 Avance nerve repairs enrolled to date
- Overall meaningful recovery rates of 82-84%; comparable to autograft outcomes without associated donor site comorbidities

MATCH℠ Registry Study: Enrollment Ongoing

- Avance outcomes compared to matched cohort of autograft and synthetic conduits

RECON℠ Study: Enrollment Complete

- Prospective, randomized, controlled study of Avance Nerve Graft vs synthetic conduits in digital injuries 5 to 25mm
- IND Pivotal Study to support BLA Submission
- Preliminary study data report expected Q2 2022, expect to file BLA in 2023

Sensation-NOW® Registry Study: Enrollment Paused*

- Multi-center clinical study in breast neurotization

REPOSE℠: Enrollment Ongoing

- Prospective, randomized, controlled study of Axoguard Nerve Cap® vs neurectomy

RETHINK PAIN™ Registry Study: Enrollment Paused*

- Designed to capture the patient's pain journey, from onset of chronic pain to nerve repair



*Enrollment was paused in Q2 2020 due to study site restrictions resulting from COVID-19. We will continue to monitor the recovery of activities at study centers and prioritize the potential restart of these clinical programs to best fit our business needs.

Growing body of clinical evidence

147

Peer Reviewed Clinical Papers*

- 98 Extremity Trauma
- 4 Breast
- 27 Oral & Maxillofacial
- 27 Pain
- 13 Other Applications



*Total number as of December 31, 2020 for the Axogen portfolio of surgical implant products. Certain publications contain data on multiple applications.

Avance Nerve Graft repairs found to be significantly better than conduit repairs

"Leversedge et al., A Multicenter Matched Cohort Study of Processed Nerve Allograft and Conduit in Digital Nerve Reconstruction" – Journal of Hand Surgery, September 2020[50]

- Peer-reviewed publication from the MATCH cohort of the RANGER Registry
- Includes outcomes from 110 subjects with 162 nerve injuries; 113 were repaired with Avance Nerve Graft and 49 were repaired with manufactured conduit
- Findings show overall meaningful recovery rate was 88% for Avance Nerve Graft and 61% for conduit (p=0.001) for gaps up to 25mm
- Average static two-point discrimination improved to 9.7mm for Avance Nerve Graft as compared to 12.2mm for conduit (p=0.018)
  - Note: lower measurement is reflective of improved discrimination and a better outcome
- As gap length increased, Avance Nerve Graft outcome rates remained consistent while conduit rates declined significantly



[1]Meaningful Recovery = ≥S3 on the MRCC Scale
*p=0.008, **p=0.001

Recent study finds Avance Nerve Graft (allograft) clinical outcomes recovery rates comparable to nerve autograft

"Safa et al., A Propensity Matched Cohort Study on Outcomes from Processed Nerve Allograft and Nerve Autograft in Upper Extremity Nerve Repairs"



Defined as MRCC Score ≥ S3/M3

Historical data on Nerve Autograft[52,53,54,55,56], Mixed Nerve: 57-80%; Digital Nerve: 60-88%

Presented at American Society for Surgery of the Hand (ASSH), Oct 2020[51]

- Study of 156 nerve repairs found meaningful recovery rates for Avance Nerve Graft were comparable to autograft for both sensory and motor function

Recent studies find Avance Nerve Graft performed comparably to nerve autograft for both clinical outcomes and facility procedure costs

"Styron et al., Nerve Repair Hospital Index Procedure Costs – Allograft vs. Autograft Repair Type"

Presented at the American Society for Surgery of the Hand (ASSH), October 2020[57]

- Data from the 2018 Medicare Standard Analytic File[58]
- 340 claims reviewed for autograft and allograft, included inpatient and outpatient procedures
- Found hospital facility procedure cost for Avance Nerve Graft was comparable to that of traditional nerve autograft
- Did not evaluate the potential additional costs associated with managing the autograft donor site and subsequent morbidities

"Styron et al., Comparative Effectiveness Evaluating Allograft, Autograft and Conduit Nerve Repairs: A **Systematic Review"**

Presented at the American Association for Hand Surgery (AAHS), January 2021[59]

- Systematic review of recovery outcomes from over 35 clinical studies and 1,500 nerve repairs with autograft, allograft and conduit repairs
- Evaluated short and long gaps for both sensory and motor outcomes
- Autograft and allograft outcome rates were found to be statistically better than conduit repairs*
- Autograft and allograft outcome rates were found to be similar, regardless of gap length or nerve function
- Cost comparison conducted with Medicare data on Hospital Index Procedure Costs for autograft and allograft were found to be similar

*Conduits only had available data for short gap sensory nerve group

First publication on breast neurotization outcomes with Avance Nerve Graft demonstrated greater return of protective sensation

"Momeni et al., Flap Neurotization in Breast Reconstruction with Nerve Allografts: 1-year Clinical Outcomes" – Plastic and Reconstructive Microsurgery Global Open, January 2021[60]



- Early outcomes from a single center study, as part of the Sensation-NOW registry
- 36 breast reconstructions that included:
  - 22 breast reconstructions with Resensation®
  - 14 standard non-neurotized breast reconstructions
- Return of Protective Sensation (p=0.04)
  - 73% of the Resensation group
  - 36% of the non-neurotized group
- Neurotization with Avance Nerve Graft resulted in greater return of sensation and return of sensation in more of the breast as compared to standard reconstruction without nerve repair.

Axogen sponsored REPOSE℠ pilot study analysis demonstrates clinically significant improvement for subjects with chronic neuropathic pain when using Axoguard Nerve Cap® following neurectomy[61]

15-subject, single arm pilot phase evaluating reduction in pain from baseline following surgical excision of the neuroma and placement of the Axoguard Nerve Cap

- Significant & clinically meaningful reduction in pain
- Significant and clinically meaningful improvements in Fatigue, Physical Function, Sleep Disturbance, Pain Interference, Pain Intensity, and Pain Behavior as measured by the validated PROMIS® measures
- Positive indicators for reduction in pain medication burden, including opioids
- No recurrence of neuroma



Minimal Clinically Important Difference (MCID): 17mm
Δ 3 months: -69 ± 23; $p < 0.0001$
Δ 12 months: -80 ± 13; $p < 0.0001$

Focused sales execution, increasing market penetration

Sales execution focused on driving results

- Continue driving penetration in active accounts and developing new active accounts
- 5,100 potential U.S. accounts perform nerve repair
- 893 active accounts as of December 31, 2020, up 12% vs PY
  - Top 10% of active accounts represent approximately 35% of total revenue

Expanded sales reach

- U.S. direct sales team
  - 111 direct sales professionals at end of Q4 2020
- Supplemented by independent agencies
- Revenue from direct sales channel represented approximately 88% of total revenue in Q4

CMS outpatient reimbursement rates improving for nerve repair using the Axogen portfolio

Although CMS rates[1] only apply to Medicare cases, which represents a small percentage of traumatic injuries, private payors are often influenced by the analysis and decisions made by CMS

CPT Code	Descriptor	C-APC	Hospital Outpatient (HOPD)				Ambulatory Surgery Center (ASC)			
			2019	2020	2021	2Y % Change	2019	2020	2021	2Y % Change
64912	Nerve allograft repair[2]	5432	$4,566	$5,508	**$5,700**	**25%**	$1,920	$3,422	**$3,788**	**97%**
64910	Conduit or vein allograft repair[2]	5432	$4,566	$5,508	**$5,700**	**25%**	$2,613	$3,133	**$3,802**	**45%**
64885	Autograft repair (head and neck ≤4cm)	5432	$4,566	$5,508	**$5,700**	**25%**	$3,575	$2,170	**$2,449**	**-31%**
64886	Autograft repair (head and neck >4cm)[3]	5432	$4,566	$5,508	**$5,700**	**25%**	$3,172	$2,170	**$4,157**	**31%**
64890	Autograft repair (hand and foot≤4cm)	5432	$4,566	$5,508	**$5,700**	**25%**	$3,075	$2,170	**$2,449**	**-20%**
64891	Autograft repair (hand and foot>4cm)[2]	5432	$4,566	$5,508	**$5,700**	**25%**	$1,920	$2,829	**$3,185**	**66%**
64892-98	Autograft repair (all other nerve type)[4]	5432	$4,566	$5,508	**$5,700**	**25%**	$1,920	$2,170	**$2,449**	**28%**
64831, 61	Direct Repair (digital, brachial plexus)[4]	5431	$4,566	$1,719	**$1,754**	**-62%**	$1,920	$797	**$809**	**-58%**
64858	Direct Repair (sciatic)[3]	5431	$4,566	$1,719	**$1,754**	**-62%**	$1,920	$797	**$1,434**	**-25%**

1. National average payment rates. Commercial payments are traditionally 1.5-2x higher than Medicare.
2. Nerve allograft repair CPT 64912, conduit repair CPT 64910 and autograft repair hand/foot >4cm CPT 64891 continue to meet ASC device intensive criteria
3. Autograft repair CPT 64886 head/neck >4cm and direct repair sciatic CPT 64858 meet ASC device intensive criteria
4. Direct repair digital and brachial plexus (64831, 64861) and autograft repair all other nerve type CPT 64892-98 do not meet ASC device intensive criteria. (excludes autograft add-on procedure codes)

Hospital inpatient rates for nerve repair align to DRGs 040, 041, 042 and range from $11.1k - $23.3k.

CMS physician fee adjustments continue to favor nerve allograft repair

CPT Codes	Descriptor	Physician Fee Schedule (PFS)			
		2019	2020	2021	2Y % Change
64912	Nerve allograft repair	$804	$ 951	**$904**	**12.4%**
64910	Conduit or vein allograft repair	$825	$820	**$803**	**-3%**
64885 to 64898*	Autograft repair	$1,096 to $1,495	$1,096 to $1,495	**$1,080 to $1,468**	**-2%**
64831 to 64868*	Direct Repair	$713 to $1,604	$717 to $1,578	**$710 to $1,565**	**-1 to -2%**

*excludes add-on procedure codes

Note: PFS rates updated to reflect the Consolidated Appropriations Act (passed Dec-27, 2020) that modified the Calendar Year (CY) 2021 Medicare Physician Fee Schedule (MPFS).

Expand the opportunity in nerve repair



Platform for nerve repair across multiple applications



Balance sheet and capital structure

Balance Sheet Highlights	December 31, 2020
Cash, Cash Equivalents, and Investments	$110.8 million
Total Long-term Debt	$35.0 million*

Capital Structure (shares)	December 31, 2020
Common Stock	40,618,766
Common Stock Options, RSUs, PSUs	5,299,389
Common Stock and Common Stock Equivalents	45,918,155

* Total long-term debt includes debt proceeds under the terms of the agreement with Oberland Capital, inclusive of unamortized debt discount and deferred financing fees.

Executive team

Karen Zaderej
Chairman, CEO, & President
J&J (Ethicon)

Peter J. Mariani
Chief Financial Officer
Guidant, Lensar, Hansen

Eric A. Sandberg
Chief Commercial Officer
Guidant

Maria Martinez
Chief Human Resources Officer
HSNi, Bausch + Lomb

Isabelle Billet
Chief Strategy & Business Development Officer
J&J, C.R. Bard, Cardinal

Brad Ottinger
General Counsel, Chief Compliance Officer
MicroPort Orthopedics

Angelo Scopelianos, Ph.D.
Chief Research & Development Officer
J&J

Erick DeVinney
VP, Clinical & Translational Sciences
Angiotech, PRA Intl

Mike Donovan
VP, Operations
Zimmer

Ivica Ducic, M.D., Ph.D.
Medical Director
Washington Nerve Institute

Mark Friedman, Ph.D.
VP, Regulatory & QA
AtriCure, Enable Medical

Axogen is the preeminent nerve repair company with a foundation for long-term sustainable growth

- ✓ Exclusively focused on peripheral nerve repair across an expanding set of applications addressing a large market opportunity
- ✓ Differentiated platform for nerve repair, anchored by Avance® Nerve Graft
- ✓ 10+ years of demonstrated clinical consistency and meaningful recovery outcomes
- ✓ 147 peer-reviewed clinical publications featuring the Axogen product portfolio
  (as of December 31, 2020)
- ✓ More than 50,000 Avance Nerve Grafts have been implanted since launch
- ✓ Avance RMAT designation highlights clinical evidence strength and unmet medical need for improved nerve injury treatments
- ✓ Commercial and Professional Education capability to convert experienced surgeons while training the next generation
- ✓ Significant barriers to competitive entry
- ✓ Solid balance sheet provides resources to execute business plan
- ✓ Experienced management team with strong track record of success

nasdaq: axgn

Deloitte Technology Fast 500: 2014, 2015, 2016, 2017, 2018, 2019

Russell 2000 Index: June 2016

DecisionWise Intl Employee Engagement Best Practices Award Winner: 2018

Footnotes

1. National Hospital Ambulatory Medical Care Survey: 2015 Emergency Department Summary Tables – Table 18. https://www.cdc.gov/nchs/data/nhamcs/web_tables/2015_ed_web_tables.pdf
2. Noble, et al.. Analysis of Upper and Lower Extremity Peripheral Nerve Injuries in a Population of Patients with Multiple Injuries. J Trauma. 1998; 45(1): 116-122.
3. Uzun, et al., Traumatic peripheral nerve injuries: demographic and electrophysiologic findings of 802 patients from a developing country. J Clin Neuromusc Dis. 2006; 7(3): 97–103.
4. Portincasa, et al. Microsurgical treatment of injury to peripheral nerves in upper and lower limbs: a critical review of the last 8 years. Microsurgery. 2007; 27(5): 455–462.
5. Medicare National HCPS Aggregate Summary Table CY2016. https://data.cms.gov/Medicare-Physician-Supplier/Medicare-National-HCPCS-Aggregate-Summary-Table-CY/jtra-d83c/data
6. Sotereanos, et al. Vein wrapping for the treatment of recurrent carpal tunnel syndrome. Tech Hand Up Extrem Surg.1997; 1(1):35-40.
7. Seradge, et al. Cubital tunnel release with medial epicondylectomy factors influencing the outcome. J Hand Surg Am. 1998; 23(3): 483-491.
8. Papatheodorou, et al. Preliminary results of recurrent cubital tunnel syndrome treated with neurolysis and porcine extracellular matrix nerve wrap. J Hand Surg Am. 2015; 40(5): 987-992
9. Lin, et al. Systematic Review and Meta-Analysis on Incidence of Altered Sensation of Mandibular Implant Surgery - PLoS One. 2016; 11(4): e0154082.
10. Hussaini. Procedure frequency in the jaws related to implant location. Dent Oral Craniofac Res. 2016; 2(2): 230-233.
11. Nguyen, et al. Risk factors for permanent injury of inferior alveolar and lingual nerves during third molar surgery. J Oral Maxillofac Surg. 2014; 72(12): 2394-2401.
12. Cheung, et al. Incidence of neurosensory deficits and recovery after lower third molar surgery: a prospective clinical study of 4338 cases. Int J Oral Maxillofac Surg. 2010; 39(4): 320–326.
13. Dental Implants Market (Product - Endosteal Implants, Subperiosteal Implants, Transosteal Implants, Intramucosal Implants; Material - Titanium Implants, Zirconium Implants; End User - Hospitals, Dental Clinics, and Academic & Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025. https://www.transparencymarketresearch.com/dental-implants-market.html
14. Cha, et al. Frequency of bone graft in implant surgery. Maxillofac Plast and Reconstr Surg. 2016; 38(1): 19.
15. Miloro, M (ed). Trigeminal Nerve Injuries. Springer; 2013.
16. Pogrel et al. Permanent nerve involvement resulting: From inferior alveolar nerve blocks. J Am Dent Assoc. 2000; 131(7): 901-907.
17. Agbaje, et al. Systematic review of the incidence of inferior alveolar nerve injury in bilateral sagittal split osteotomy and the assessment of neurosensory disturbances. Int. J Oral Maxillofac. Surg. 2015; 44(4): 447-451.
18. ASPS 2017– Plastic Surgery Statistics Report. www.plasticsurgery.org/documents/News/Statistics/2017/plastic-surgery-statistics-full-report-2017.pdf
19. Rappaport, et al. Clinical utilization and complications of sural nerve biopsy. Am J Surg. 1993; 166(3): 252-256.
20. Weber, et al. A randomized prospective study of polyglycolic acid conduits for digital nerve reconstruction in humans. Plast Reconstr Surg. 2000; 106(5): 1036-1045.
21. Wangensteen, et al. Collagen tube conduits in peripheral nerve repair: A retrospective analysis. Hand. 2010; 5(3): 273-277.
22. Data on file at Axogen
23. Karabekmez, et al. Early clinical outcomes with the use of decellularized nerve allograft for repair of sensory defects within the hand. Hand. 2009; 4(3): 245-249.
24. Boeckstyns, et al. Collagen conduit versus microsurgical neurorrhaphy: 2-year follow-up of a prospective, blinded clinical and electrophysiological multicenter randomized, controlled trial. J hand Surg Am. 2013; 38(12): 2405-2411.
25. Brushart, et al. Selective reinnervation of distal motor stumps by peripheral motor axons. Exp Neurol. 1987; 97(2): 289-300.
26. Schmidhammer, et al. Alleviated tension at the repair site enhances functional regeneration: The effect of full range of motion mobilization on the regeneration of peripheral nerves--histologic, electrophysiologic, and functional results in a rat model. J Trauma. 2004; 56(3): 571-584.
27. Tang, et al. The optimal number and location of sutures in conduit-assisted primary digital nerve repair. J Hand Surg Eur Vol. 2018; 43(6): 621-625.
28. Data on file at Axogen
29. Badylak, et al. Small intestinal submucosa: A substrate for in vitro cell growth. J Biomater Sci Polym Ed. 1998; 9(8): 863-878.
30. Hodde, et al. Effects of sterilization on an extracellular matrix scaffold: Part II. Bioactivity and matrix interaction. J Mater Sci Mater Med. 2007; 18(4): 545-550.
31. Nihsen, et al. Bioactivity of small intestinal submucosa and oxidized regenerated cellulose/collagen. Adv Skin Wound Care. 2008; 21(10): 479-486.
32. Hodde, et al. Vascular endothelial growth factor in porcine-derived extracellular matrix. Endothelium. 2001; 8(1): 11-24.
33. Data on file at Axogen
34. Kokkalis, et al. Assessment of processed porcine extracellular matrix as a protective barrier in a rabbit nerve wrap model. J Recon MicroSurg. 2011; 27(1): 19-28.
35. Data on file at Axogen
36. Data on file at Axogen

Footnotes

37. Mitchell A Pet, Jason H Ko, Janna L Friedly, Douglas G SmithTraction. Neurectomy for Treatment of Painful Residual Limb Neuroma in Lower Extremity Amputees J Orthop Trauma. 29 (9), e321-5 Sep 2015.
38. Laborde K, et al. Results of surgical treatment of painful neuromas of the hand. The Journal of Hand Surgery. March 1981;7(2):190-193.
39. Galeano M, et al. A free vein graft cap influences neuroma formation after nerve transection. Microsurgery. 2009;29(7):568-572.
40. Stokvis A. Surgical management of painful neuromas. Rotterdam, The Netherlands: Optima Grafische Communicatie; 2010.
41. Lin E, et al. Local administration of norephinephrine in the stump evokes dose-dependent pain in amputees. Clin J Pain. 2006;22(5):482-486.
42. O'Reilly MA, et al. Neuromas as the cause of pain in the residual limbs of amputees. An ultrasound study. Clin Radiology. May 1-6, 2016.
43. Rajput K, et al. Painful neuromas. The Clinical Journal of Pain. 2012;28(7):639-645
44. Gruber H, et al. Practical experience with sonographically guided phenol instillation of stump neuroma: predictors of effects, success, and outcome. Am J Roentgenol. 2008;190(5):1263-1269.
45. Fallat L. Cryosurgery or sclerosing injections: which is better for neuromas. Podiatry Today. 2004;17(6):58-66.
46. Bradley MD. Plantar neuroma: analysis of results following surgical excision in 145 patients. South Med J. 1976;69:853-845.
47. Kehoe S, et al. FDA-approved guidance conduits and wraps for peripheral nerve injury: A review of materials and efficacy. Injury. 2012;43:553-572.
48. Record RD, Hillegonds D, Simmons C, Tullius R, Rickey FA, Elmore D, Badylak SF. In vivo degradation of 14C-labeled small intestinal submucosa (SIS) when used for urinary bladder repair. Biomaterials. 2001 Oct;22(19):2653-9.
49. Safa B, Jain S, Desai MJ, Greenberg JA, Niacaris TR, Nydick JA, Leversedge FJ, Megee DM, Zoldos J, Rinker BD, McKee DM, MacKay BJ, Ingari JV, Nesti LJ, Cho M, Valerio IL, Kao DS, El-Sheikh Y, Weber RV, Shores JT, Styron JF, Thayer WP, Przylecki WH, Hoyen HA, Buncke GM.Peripheral nerve repair throughout the body with processed nerve allografts: Results from a large multicenter study. Microsurgery. 2020 Jul;40(5):527-537.
50. Leversedge FJ, Zoldos J, Nydick J, Kao DS, Thayer W, MacKay B, McKee D, Hoyen H, Safa B, Buncke GM. A Multicenter Matched Cohort Study of Processed Nerve Allograft and Conduit in Digital Nerve Reconstruction. J Hand Surg Am. 2020 Dec;45(12):1148-1156.
51. Safa B, Power D, Liu A, Thayer WP, et al. A Propensity Matched Cohort Study on Outcomes from Processed Nerve Allograft and Nerve Autograft in Upper Extremity Nerve Repairs. In: The 75th Annual Meeting of the ASSH. Virtual Annual Meeting, October 1-2, 2020.
52. Sallam AA, El-Deeb MS, Imam MA. Nerve Transfer Versus Nerve Graft for Reconstruction of High Ulnar Nerve Injuries. J Hand Surg Am. 2017 Apr;42(4):265-273
53. Roganovic Z, Pavlicevic G. Difference in recovery potential of peripheral nerves after graft repairs. Neurosurgery. 2006 Sep;59(3):621-33; discussion 621-33.
54. Frykman G, Gramyk K. Results of nerve grafting. In: Gelberman R, ed. Operative nerve repair and reconstruction. Philadelphia: JB Lippincott, 1991:553–567.
55. Vastamäki M, Kallio PK, Solonen KA. The results of secondary microsurgical repair of ulnar nerve injury. J Hand Surg Br. 1993 Jun;18(3):323-6.
56. Kallio PK, Vastamäki M, Solonen KA. The results of secondary microsurgical repair of radial nerve in 33 patients. J Hand Surg Br. 1993 Jun;18(3):320-2.
57. Styron JF, Thompson AK, Park LI, Watson GJ. Nerve Repair Hospital Index Procedure Costs – Allograft vs. Autograft Repair Type. In: The 75th Annual Meeting of the ASSH. Virtual Annual Meeting, October 1-2, 2020.
58. U.S. Centers for Medicare and Medicaid Services, Medicare Claims standard analytic file. 2018.
59. Styron JF, Lans-Valera J Comparative Effectiveness Evaluating Allograft, Autograft and Conduit Nerve Repairs: A Systematic Review. American Association for Hand Surgery. Virtual Annual Meeting, January 2021
60. Data on file at Axogen.
61. Momeni A, Meyer S, Shefren K, Januszyk M. Flap Neurotization in Breast Reconstruction with Nerve Allografts: 1-year Clinical Outcomes. Plast Reconstr Surg Glob Open. 2021 Jan 12;9(1):e3328